Infusion Options, Inc., Brooklyn, NY

Is Infusion Options, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does Infusion Options, Inc. hold a New York pharmacy license?

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions.

Has Infusion Options, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter (Aug 26, 2021) for Infusion Options, Inc. State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Infusion Options, Inc.
Location
Brooklyn, NY
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
2
Warning letters on FDA’s actions page
1
Latest action on that page
Aug 26, 2021
FDA Data Dashboard inspections
2 inspections: 2 OAI; 2 published Form 483s
Form 483 text on this page
3 Form 483s, 25 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Infusion Options, Inc., a 503A facility, with 3 dated actions.

Document
Aug 26, 2021Warning letterWarning Letter (08/26/2021)FDA copy (archived)
Jul 8, 2019Amended Form 483Amended 483 Issued 07/08/2019FDA copy (archived)
Jun 25, 2019Form 483483 Issued 06/25/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Infusion Options, Inc., Brooklyn, NY (FEI number 3008231170), matched to this page by exact name, city and state. It lists 2 inspections: 2 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jun 1, 2017Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30082311701012329
Apr 23, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3008231170875614

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 25 numbered observations in all, across 3 inspections ending Jun 1, 2017 to Jun 25, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection May 30, 2019 to Jun 25, 2019: 1 observation

Firm on the cover
Infusion Options, Inc., 745 64th Street, Brooklyn, NY 11219-4934
FEI number
3015452722
Establishment type on the cover
Warehouse
FDA district office on the cover
158-15 Liberty Avenue Jamaica, NY 11433
Matched to this page by
firm name, city and state on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Drug products are not stored under appropriate conditions of temperature and humidity so that their identity, strength, quality, and purity are not affected.

Specifically, on 05/30/2019, we observed lblli" boxes of drug products within expiry, stored on the floor of the pharmacy compounding room under filthy and uncontrolled temperature/humidity conditions. This facility is considered an "inactive

compounding pharmacy", which is not maintained clean with the presence of dead insects and dirty floors within drug storage rooin and at the moment of the inspection there were no temperature controls to assure that the drug products were maintained in adequate storage conditions. Some of the drug product found under these conditions include but not limited to:

the

- Ox.aliplatin Injection 50mg/10mL, Lot-# <Redacted B4> Exp: 07-2020

-<Redacted B4> (bortezomib) for Injection 3.5mg/vial, Lot <Redacted B4> Exp:05-2020

- Placitaxel Injection, USP 30mg/5mL, Lot# <Redacted B4> Exp:07-2020

-(<Redacted B4> or Injectable Suspension, 100mg/vial, Lot# <Redacted B4> Exp:04-2021

Inspection May 6, 2019 to Jun 25, 2019: 17 observations

Firm on the cover
Infusion Options, Inc., 5924 13th Ave, Brooklyn, NY 11219-4 934
FEI number
3008231170
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
158-15 Liberty Avenue Jamaica, NY 11433
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (Internet Archive copy FDA links)

Observation 1

Dmg products are not stored under appropriate conditions of temperature and humidity so that their identity, strength, quality, and purity are not affected.

Specifically, on 05/16/2019, we observed <Redacted B4> coolers with drug products within expiry that require temperature-contrnlled conditions (e.g. 2°-8°C) stored on the floor of the warehouse bathroom that appeared to be actively used as such. Your firm failed to store drug products under sanitary and temperature-controlled conditions. Some of the products found under these conditions include but not limited to:

<Redacted B4> lbevacizumab) 400mg/16mL (25mg/mL), Lot# <Redacted B4> Exp: 02-2021

(P,J, <Redacted B4> Riituximab) IO0mg/10mL ( l~mg/mL Lot# <Redacted B4> Exp: 07-2021

- (D) (4)

- ( b) ( 4) - ( b) ( 4) - ~ b) ( 4)

<Redacted B4> carfilzomib) 60mg/vial, Lot# <Redacted B4> Exp: 01-2021

<Redacted B4> (Infliximab) 1 00mg/vial, Lot# <Redacted B4> Exp: 10-2021

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.

Specifically, during the aseptic processing of sterile drug products we observed the following aseptic technique deficiencies:

AM ENDMENT 1

1) During compounding of Penicillin G, batch# PEN250508190800 on 05/08/2019:

a. The operator moved her rums and hands over bottles, bags, syiinges and needles multiple times ( over 10 times) dming the manufacturing process, disrnpting the ISO-5 HEPA airflow over the compounded product and materials below her rums.

b. The operator wiped the injection poit of the 5% Dextrose Injection, USP, 100 ml bags, '<Redacted B4> bags) for disinfection, however the poits stayed in direct contact with the ISO-5 counter smface, eaving the poits exposed to any prut iculate or bacteiia flushed by the vertical airflow onto the BSC work surface.

c. After wiping the injection poit with an <Redacted B4> the operator did not allow enough contact time for disinfection and the poit to diy, then he immediately proceeded to inject the penicillin into the 5% Dextrose Injection, USP, 100ml bags.

f41 ...

Read the full 483 (Internet Archive copy FDA links)

Observation 3

Unauthorized personnel have access to enter areas of the buildings and facilities designated as limited access areas.

Specifically, during the r view of video camera footage of the Ante Room ISO-8 area <Redacted B4> rooms for the period of 05/08/2019 to 05/16/2019, we observed personnel with no documented traming and or education on conducting processes in these areas. (e.g. it was observed an Infusion Options Inc. chiver entering the aseptic areas ungowned and canying compounding materials and products into the ISO-7 areas).

Observation 4

Written production and process contrnl procedures are not followed in the execution of production an d process control functions.

Your firm's pharmacist and technician failed to identify and collect adequate compounding materials prior to the compounding of Rx <Redacted B4> Piperacillan-Tazobactam ;,5gm/l0ml D5W IV. Specifically, on 6/7/2019, it was observed <Redacted B4> bags of expired Dextrose 5% IV bags lot# <Redacted B4> Exp: May 2019 used for the preparation of <Redacted B4> add-a-vials Intra Venous drugs.

Observation 5

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically:

a) Your fnm does not conduct continuous non-viable pruticulate testing in the ISO 5 areas, during aseptic processing. Currently your firm conducts the non-viable particulate testing every <Redacted B4> during the equipment certifications.

b) The HEPA filters on the ISO-5 <Redacted B4> Benches <Redacted B4> and <Redacted B4> were observed with what appeared to be moist stains and signs of deterioration.

AMENDMENT 1

Observation 6

Aseptic processing areas are deficient in that walls are not smooth an d/or hard surfaces that are easily cleanable.

Specifically, the wall in the <Redacted B4> room ISO 7 grade, which are used for aseptic processing of Total parenteral nutrition (TPN) products, had paint peeling under the thermostat making this area porous and iITegular.

Observation 7

Samples taken of drug products for determination of conformance to written specifications are not representative.

Specifically, your firm does not collect samples for testing that are representative of the entfre aseptic processes. (e.g. During mfg. of Penicillin G, batch# PEN250508190800 we observed that your firm manufactured <Redacted B4> bags of product from " 1 separate bottles of <Redacted B4> Penicillin G, however collected the last mixed LI ags as samples for testing from the last of the lb bottles of Penicillin G.)

Observation 8

Written records of major equipment cleaning, maintenance and use are not included in individual equipment logs.

Specifically, your firm does not maintain usage/maintenance logs for any of the Lamina! Air Flow and Bio Safety Cabinets used for the manufactming of drug products, to document when the equipment was used, the products manufactured and cleaning and maintenance of the equipment.

Observation 9

AM ENDMENT 1

Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.

Therefore, failing to comply with section 503B(b )(2)(A). Specifically, the following products were compounded and not identified on your report dated December 2018:

Daptomycin 800 MG/ 50 ML 0.9% NACL IV-(e.g. <Redacted B4> dated 8/1/2018)

• • Heparin 30 units/3 mL flush Syringe -(e.g. Rx# <Redacted B4> 6/26/2018)

Ferric Carboxymaltose 750 mg/50 mL NS-(e.g. Rx# <Redacted B4> dated 7/25/2018)

Bortezomib 2.25 MG / 0.9 mL SQ Syringe-(e.g. Rx# <Redacted B4> date 7/25/2018)

Bevacizumab 691 MG / 100 ML NS IVPB-(e.g. Rx#t <Redacted B4> date 9/18/2018)

Observation 10

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically, your fnm failed to conduct endotoxin testing on intrathecal drug products aseptically processed in your facility such as but not limited to:

Rx <Redacted B4> Methotrexate 15 mg QS 6 mL NS IT, date 11/06/2018

• • Rx <Redacted B4> Methotrexate 15 mg QS 6 mL NS IT, date 05/16/2019

Rx <Redacted B4> Cytarabine 70 mg QS 3 mL PF NS Syringe, date 07/1 7/2018

Rx <Redacted B4> -Cytarabine 100 mg QS 6 mL PF NS Syringe, date 05/23/2019

Observation 11

Written records are not made of investigations into unexplained discrepancies and the failure of a batch or any of its components to meet specifications.

Specifically, your firm does not conduct and document investigations when drug product fails to meet specifications such as potency, sterility and endotoxin. For example:

a. Cefazolin Sodium 2mg-Lot# CEFAZ20306180900, Mfg. date 3/6/2018 <Redacted B4> ISample # <Redacted B4> Potency Laboratory results-89.0% (Specification <Redacted B4>%)

AM ENDMENT 1

c. Penicillin G 2.5 Million Units/ l OOmL Dextrose 5%-Lot# PEN250518180810, Mfg. date 5/18/2018 <Redacted B4> Sample # <Redacted B4> Potency Laboratory results-86.0% (Specification <Redacted B4> %

Observation 12

The labels of your outsourcing facility's drug products are deficient.

They do not include information required by section 503B(a)(lO)(A). The statements, "This is a compounded drug " and "Not for resale," the lot or batch number, and the date the drug was compounded are not on your drug product labels. Labels for the following drug products do not contain these statements:

Rx# <Redacted B4> -Daptomycin 1000 mg/50 mL 0.9% NACL IV, discard date: 05/16/19

Rx# <Redacted B4> -Hepruin 30 units/3 mL flush sy1inge, discru·d date: 08/05/19

Rx# <Redacted B4> Vancomycin 1000 mg/250 mL D5W IVPB, discard date: 05/16/19

• • Rx# <Redacted B4> Ferric Carboxymaltose 750 mg/50 mL NS, discard date: 05/08/19

Rx# <Redacted B4> Pembrolizumab 200 mg/100 mL NS IVPB, discard date: 04/30/19

Observation 13

The container labels of your outsourcing facility's drug products are deficient.

The container of your outsourcing facility's drug products does not include information required by section 503B(a)(IO)(B). Specifically, your outsourcing facility's drug product container labels do not contain information to facilitate adverse event reporting: http://www.fda.gov/medwatch and 1-800-FDA-1088. Container labels for the following drug products do not contain this information:

Rx# <Redacted B4> Daptomycin 1000 mg/50 mL 0.9% NACL IV, discard date: 05/16/19

Rx# <Redacted B4> Hepruin 30 units/3 mL flush syringe, discard date: 08/05/19

Rx# <Redacted B4> Vancomycin 1000 mg/250 mL D5W IVPB, discard date: 05/16/19

AMENDMENT 1

Rx# <Redacted B4> Pembrolizumab 200 mg/100 mL NS IVPB, discard date: 04/30/19

Observation 14

The written stability testing program is not followed.

Specifically, your firm does not conduct stability studies on your prescription drug products such as but not limited to:

Rx# <Redacted B4> -Daptomycin 1000 mg/50 mL 0.9% NACL IV, discard date: 05/16/19

Rx# <Redacted B4> -Hepruin 30 units/3 mL flush syringe, discard date date: 08/05/19

Rx# <Redacted B4> Vancomycin 1000 mg/250 mL D5W IVPB, discard date: 05/16/19

• • Rx# <Redacted B4> Ferric Carboxymaltose 750 mg/50 mL NS, discard date: 05/08/19

Rx# <Redacted B4> Pembrolizumab 200 mg/100 mL NS IVPB, dicard date: 04/30/19

Observation 15

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, your firm does not conduct potency and sterility testing for all prescription drug product aseptically processed at your facility such as:

Rx# <Redacted B4> Daptomycin 1000 mg/50 mL 0.9% NACL IV, discard date: 05/16/19

Rx# <Redacted B4> -Hepruin 30 units/3 mL flush sy1inge, discard date: 08/05/19

Rx# <Redacted B4> Vancomycin 1000 mg/250 mL D5W IVPB, discard date: 05/16/19

• • Rx# <Redacted B4> Ferric Carboxymaltose 750 mg/50 mL NS, discard date: 05/08/19

Rx# <Redacted B4> Pembrolizumab 200 mg/100 mL NS IVPB, discard date: 04/30/19

Observation 16

AMENDMENT 1

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.

Specifically, your firm failed to maintain separate storage areas out of the ISO-7 areas. Currently your firm is using refrigerators in the <Redacted B4> ISO-7 room for the storage of commercial drug products used in the aseptic processing of drug products

Note: Refiigerators are pruticle generators that can affect the ISO-5 and ISO-7 area, that could affect product quality.

Observation 17

Your outsourcing facility compounds drug products that have been withdi·awn or removed from the market because such drugs or components of such drugs have been found to be unsafe or not effective.

Specifically,

Ondansetron 24 mg/50 rnL D5W IVPB

Inspection Jun 1, 2017: 7 observations

Firm on the cover
, 5924 13th Ave Infusi on Options , Inc.
FEI number
3008231170
Establishment type on the cover
Pharmaceutical Outsourcing Facility Brookl yn , NY 11219-4 934
FDA district office on the cover
158-1 5 Libert y Avenue Jamaica, NY 11433
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

Specifically:

Media fills (aseptic process simulations) are not representative of routine production in that the number of units filled is not representative of a typical compounded batch and the current practice as recorded in written reports of media fills do not address the need to incorporate worst case activities and challenging conditions.

Observation 2

Clothing of personnel engaged in the of drug products is not appropriate for the duties they perform. Specifically: Observation of aseptic operations found evidence of poor gowning practice in th at of the two pharmacists i

a bag of sterile c omponents w ith the cuff of REDACTED (b) (6), (b) (7)(C) steril

nvolved in compound ing operations, one was observed to be reaching into

REDACTED (b) (6), ( b) (7)(C) wrist was visible. The other pharmacist was observed to have REDACTED (b) (6), (b) (7)(C)mask g

e glove below the e nd of the gown sleeve and

radually moving dow n (b) (6), (b) (7)(C) nose and throughout a long period o

f the compounding o peration the mask continued to slide further down

(b) (6), (b) (7)(C ) nose. In the case of the latter referenced individual, REDACTED (b) (6), (b) (7)(C) made numerous efforts to correct the mask using REDACTED (b) (6), (b) (7)(C) gloved hand and did not make an effort tore-gown as necessary to correct the problem.

Observation 3

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically:

Observation of aseptic operations from beginning to end found that the individual responsible for active viable sampling conducted all air sampling after operations were completed and without personnel present rather than performing it during operations.

The firm's environmental monitoring and personnel monitoring procedures state that REDACTED (b) (4) Inspection found that the firm is not following their own procedures and TSA plates incubated in-house as well as TSA plates submitted to an external laboratory are incubated only at about REDACTED (b) (4) centigrade for growth and recovery of aerobic bacteria. There is no documented monitoring of the temperature of the incubator used for the incubation of active air sampling TSA plates.

Observation 4

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically:

Compounded batches of drug products are not tested for potency.

Observation 5

Each batch of drug product purporting to be pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically:

Compounded batches of drug products are not tested for endotoxin.

Observation 6

The labels of your outsourcing facility's drug products are deficient.

Specifically:

The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A) and (B). Specifically,

Your outsourcing facility's drug product labels do not contain a list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient. Examples of drug products labels that do not contain this information:

o o o o o o o o o o

Oxytocin 20 Units added to 1000 mL Lactated Ringers Injectable Bag Cefazolin 1 gram added to 50 mL D5W Injectable Bag Cefazolin 2 gm in 10 mL of0.9% NaCl Injectable Syringe Penicillin G Potassium 2.5 Million Units in 100 mL ofD5W Injectable Bag

Bivalirudin 250 mg in 50 mL D5W Injectable Bag Ceftriaxone 1 gm in 50 mL D5W Injectable Bag Ceftriaxone 2 gm in 50 mL D5W Injectable Bag Ampicillin-Sulbactam 3 gm in 100 mL 0.9% NaCl Injectable Bag Ampicillin-Sulbactam 1.5 gm in 100 mL 0.9% NaCl Injectable Bag Piperacillin-Tazobactam 3.375 gm in 50 mL D5W Injectable Bag

Observation 7

The responsibilities and procedures applicable to the quality control unit are not fully followed.

Specifically:

Your outsourcing facility did not submit a report to FDA identifying products compounded during the previous six months for the December 2016 reporting period as required by section 503B(b )(2)(A). Specifically, the following products, as examples, were compounded between June 1, 2016, and November 30, 2016, but were not identified on your report dated December 20, 2016:

Ceftriaxone 2 gm in 50 mL D5W Injectable Bag Aztreonam 2 gm in 50 mL D5W Injectable Bag Ceftazidime 1 gm in 50 mL D5W Injectable Bag Pantoprazole 40 mg in 100 mL 0.9% NaCl Injectable Bag Ampicillin 1 gm in 50 mL D5W Injectable Bag

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.